The manufacturing execution system in life sciences market size is projected to reach US$ 10,456.54 million by 2033 from US$ 3,139.14 million in 2022. The market is expected to register a CAGR of 12% during 2023–2033. A shift from legacy to modern MES is likely to remain a key trend in the market.
Modern MES solutions are embracing more aspects of enterprise resource planning (ERP) platforms. This allows them to offer better logistics tracking, material identity, and integration with the production operations, together with a distributed model that surpasses traditional production. Moreover, traditional MES solutions are focused on batch manufacturing and are often incapable of necessary capabilities without significant customization. In the forecast period, such factors are expected to promote the adoption of modern manufacturing execution systems among life science researchers.
The manufacturing execution system (MES) is a dynamic, comprehensive solution that helps track, document, monitor, and control the process of manufacturing goods, from raw materials to finished products. These solutions also provide the decision-makers with multivariate data that can be utilized to optimize plant floor operations and enhance production efficiency. MES can have extended functionalities, typically referred to as manufacturing operations management (MOM) functions. The term “manufacturing operations management” is defined as Level 3 of the ANSI/ISA-95 Enterprise-Control System Integration standard.
MES can help manufacturers function with a lower workforce, gather accurate real-time data from the production process, increase process efficiency and flexibility, safeguard regulatory expectations, and digitize the manufacturing process.
In February 2022, Integerannounced that it had acquired Critical Manufacturing's Manufacturing Execution System (MES) to enhance the efficiency and quality of its global production processes. The company will utilize this module at its site in Ireland to digitize its production processes, gather real-time data, and enhance efficiency, quality, and traceability. Similarly, in September 2020, Körber and Walvax Biotechnology announced that it had signed an agreement to implement Werum PAS-X MES, the MES for pharma, biotech, and cell & gene therapy manufacturing, at its Yuxi plant for vaccine production. As per Körber, PAS-X MES allows the user to manage, visualize and analyze data fast, comprehensively, and in real time. In August 2019, Takeda Ireland Ltd. implemented PAS-X MES in a phased approach at its Grange Castle, Ireland, production site and transformed it into a paperless factory. Such growing adoption of MES by the market players for gathering accurate real-time data in the production management process is boosting the growth of manufacturing execution systems in life science market. In addition, modern MES solutions (often referred to as light MES) are highly flexible, tailored as per requirements, integrate various tools, and are cloud-based. Further, the MES and Laboratory Execution Systems (LES) can also help reduce the risk of contamination, improve data integrity, lower operating costs, ensure regulatory compliance and quality, and enhance track and trace capabilities. Because of all the above advantages of using MES, various market players are adopting the system.
There is also an increasing number of collaborations between key solution providers of the pharmaceutical manufacturing industry’s ecosystem for developing advanced solutions for cell and gene therapy product manufacturing. In January 2022, TrakCe collaborated with Korber for software integration. The collaboration resulted in a functional integration between TrakCel’s OCELLOS and Körber’s PAS-X. It is expected to allow both companies' cell and gene therapy customers to effectively share data detailing manufacturing events and milestones such as starting checks, fill and finish, and product release; and provide full traceability and audit logs. In October 2021, Körber and Vineti announced that they were partnering to integrate Korber’s PAS-X MES with Vineti’s industry-leading Personalized Therapy Management (PTM) platform. This partnership will further empower biopharma customers with an integrated PAS-X MES solution, which will help bring life-saving cell and gene-based therapies to patients in need. Thus, the growing application and adoption of MES by the market players in cell and gene therapy manufacturing is expected to create an opportunity for the growth of the manufacturing execution system in life science market during the forecast period.
Key segments that contributed to the derivation of the manufacturing execution system in life sciences market analysis are offering, deployment, organization size and application.
The geographic scope of the manufacturing execution system in life sciences market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. In North America, technological innovations are projected to offer growth opportunities for the manufacturing execution system in life science market. Further, the rising digitization of manufacturing processes in the pharmaceutical industry is fueling the growth of the manufacturing execution system in life science market in the region. In addition, the presence of market players such as Apprentice FS, Inc; Atachi Systems; Emerson Electric Co; POMS Corporation; and Rockwell Automation, which are continuously working on easing the manufacturing processes in the healthcare industry, is boosting the growth of the manufacturing execution system in life science market.
The regional trends and factors influencing the Manufacturing Execution System in Life Sciences Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Manufacturing Execution System in Life Sciences Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 3,139.14 Million |
| Market Size by 2033 | US$ 10,456.54 Million |
| Global CAGR (2022 - 2033) | 12% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2033 |
| Segments Covered |
By Offering
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Manufacturing Execution System in Life Sciences Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Manufacturing Execution System in Life Sciences Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The manufacturing execution system in life sciences market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the manufacturing execution system in life sciences market are listed below:
The “Manufacturing Execution System in Life Sciences Market Size and Forecast (2023–2033)” report provides a detailed analysis of the market covering below areas:
The global manufacturing execution system in life sciences market is expected to reach US$ 10,456.54 million by 2033.
The expected CAGR of the global manufacturing execution system in life sciences market is 12%.
Shift from legacy to modern MES is anticipated to play a significant role in the global manufacturing execution system in life sciences market in the coming years.
The key players holding majority shares in the global manufacturing execution system in life sciences market are Siemens AG, Emerson Electric, Schneider Electric, Rockwell Automation, Apprentice FS Inc, ATS Global, Atachi Systems, LZ Lifescience Ltd, and POMS Corporation.
North America dominates the manufacturing execution system in life sciences market.
The requirement of accurate real-time data in the production management process and rising application in cell and gene therapy manufacturing are the major factors that propel the global manufacturing execution system in life sciences market.